What type of study is this?

September 10, 2025Future OncologyOpen Access

Community hematologist/oncologist perspectives on minimal residual disease testing in patients with multiple myeloma

View Full Paper

Ask AI

Bookmark

Authors

LGLucio GordanFlorida Cancer Specialists & Research Institute AWAmanda N. WarnerThe University of Texas MD Anderson Cancer Center THTrevor HeritageFlorida Cancer Specialists & Research Institute

Discussion

Member takes

Implication

Survey reveals community oncologists' views on minimal residual disease testing in multiple myeloma, highlighting its clinical decision-making impact.

Key Points

Community hematologists and oncologists report varied approaches to minimal residual disease testing in multiple myeloma.
Testing influences clinical decision-making, with emphasis on adapting treatment based on MRD results.
Barriers include access to MRD testing and understanding of clinical implications among patients and providers.
Patterns of MRD testing usage vary significantly across different healthcare practice settings.

Cite This Study

Gordan et al. (2025) studied this question.

synapsesocial.com/papers/68c1cc3754b1d3bfb60f45d8 https://doi.org/10.1080/14796694.2025.2546284

View Full Paper

Ask AI

Bookmark

Implication

Survey reveals community oncologists' views on minimal residual disease testing in multiple myeloma, highlighting its clinical decision-making impact.

Community hematologist/oncologist perspectives on minimal residual disease testing in patients with multiple myeloma

Discussion

Member takes

Implication

Key Points

Cite This Study

Community hematologist/oncologist perspectives on minimal residual disease testing in patients with multiple myeloma

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider